XOMA (XOMA Royalty) ROCE %: 13.13% (As of Mar. 2026)


XOMA XOMA Royalty Corp XOMA
45 GF Score
Price $42.15
GF Value $18.85
Valuation Significantly Overvalued
! 9 Warning Signs
View Full Analysis

What is XOMA Royalty ROCE %?

XOMA Royalty XOMA -0.12% 45 ROCE % is 13.13% as of Mar. 2026. GuruFocus rates XOMA with a GF Score™ of 45/100 and a GF Value™ of $18.85 (Significantly Overvalued). The stock has 9 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. XOMA Royalty's annualized ROCE % for the quarter that ended in Mar. 2026 was 13.13%.

XOMA Royalty  (NAS:XOMA) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

XOMA Royalty ROCE % Related Terms

XOMA Royalty ROCE % Historical Data

* Premium members only.

The historical data trend for XOMA Royalty's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

XOMA Royalty ROCE % Chart

XOMA Royalty Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 12.27 -11.92 -23.11 -2.74 20.63

XOMA Royalty Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.99 25.21 31.87 15.54 13.13
XOMA
45GF Score
XOMA Royalty Corp XOMA
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

XOMA Royalty ROCE % Calculation

XOMA Royalty's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=44.846/( ( (221.277 - 24.374) + (272.698 - 34.82) )/ 2 )
=44.846/( (196.903+237.878)/ 2 )
=44.846/217.3905
=20.63 %

XOMA Royalty's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=31.3/( ( (272.698 - 34.82) + (271.858 - 33.077) )/ 2 )
=31.3/( ( 237.878 + 238.781 )/ 2 )
=31.3/238.3295
=13.13 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 13.13% mean?
XOMA Royalty (XOMA) has a ROCE % of 13.13% as of Mar. 2026.
Is XOMA Royalty's ROCE % too high?
XOMA Royalty's current ROCE % is 13.13%. Overall, XOMA Royalty has a GF Score™ of 45/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does XOMA Royalty's ROCE % compare to EDIT and FDMT?
XOMA Royalty's ROCE % of 13.13% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. XOMA Royalty's current ROCE % is 13.13%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is XOMA Royalty stock overvalued right now?
Based on GuruFocus' analysis, XOMA Royalty (XOMA) is currently considered Significantly Overvalued. The stock's GF Value™ is $18.85, compared to a current price of $42.15 — trading 123.6% above its estimated fair value. The current ROCE % is 13.13%. XOMA Royalty's overall GF Score™ is 45/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For XOMA Royalty (XOMA), the current ROCE % is 13.13% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is XOMA Royalty (XOMA) Overvalued in 2026?

Based on GuruFocus' analysis, XOMA Royalty stock appears to be overvalued. The current stock price of $42.15 is trading 123.6% above its estimated GF Value™ of $18.85. GuruFocus considers XOMA Royalty to be Significantly Overvalued.

Key valuation signals for XOMA:

  • ROCE %: 13.13%
  • GF Value™: $18.85 vs. price of $42.15 (123.6% above fair value)
  • GF Score™: 45/100 with 9 warning signs

No single metric tells the full story. See the XOMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

XOMA Royalty Business Description

Address 2200 Powell Street, Suite 310, Emeryville, CA, USA, 94608
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates. The Company's drug royalty aggregator business is mainly focused on the acquisition of early to mid-stage clinical assets. Geographically, the company operates in Switzerland, the United States, Asia Pacific, Europe, and other regions.
45GF Score

Get the complete analysis for XOMA

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$42.15
Price
$18.85
GF Value